How much money does covid-19 self-test reagent make overseas Andon Health Co.Ltd(002432) released performance forecast and express may be used as a reference.
Andon Health Co.Ltd(002432) released data show that the company’s net profit attributable to shareholders of listed companies and net profit deducted in the first quarter are expected to be 14-16 billion yuan. The net profit attributable to shareholders of listed companies increased by 367.07-419.66 times year-on-year and net profit deducted increased by 738452843960 times year-on-year.
As of the closing on April 12, covid-19 hot stock Andon Health Co.Ltd(002432) ( Andon Health Co.Ltd(002432) , SZ) rose by the limit to close at 74.47 yuan / share.
attributable net profit increased 360 times in advance
On the news side, Andon Health Co.Ltd(002432) disclosed the annual performance express of 2021 and the performance forecast of the first quarter of 2022. Influenced by the company’s covid-19 antigen home self-test OTC kit obtained the U.S. Food and Drug Administration’s (FDA) emergency use authorization (EUA) in November 2021 and the development of Omicron epidemic in the United States, Andon Health Co.Ltd(002432) 2021 achieved a total operating revenue of 2.513 billion yuan, a year-on-year increase of 25.11%; The net profit attributable to the parent company was 913 million yuan, a year-on-year increase of 276.87%; Deduct non net profit of 832 million yuan, an increase of 236.03% year-on-year.
Similarly, affected by the development of the epidemic in the United States, the company’s net profit and net profit attributable to shareholders of Listed Companies in the first quarter are expected to be 14 billion to 16 billion yuan. The net profit attributable to shareholders of listed companies increased by 367.07 to 419.66 times year-on-year, and the net profit attributable to shareholders of listed companies increased by 738452 to 843960 times year-on-year.
This astonishing figure exceeded the record of A-share market’s “pre increase king” Beijing Hotgen Biotech Co.Ltd(688068) ( Beijing Hotgen Biotech Co.Ltd(688068) , SH; yesterday’s closing price of 190.18 yuan) in the first quarter of last year, with non net profit deduction increasing by more than 1000 times. However, the factors that triggered the performance of the two IVD (in vitro diagnostic products) companies are the same, that is, the export business of covid-19 test kit.
Regarding the change of the company’s performance in the first quarter, Andon Health Co.Ltd(002432) said that the local demand for covid-19 antigen detection kit products increased significantly due to the development of the epidemic in the United States. Ihealth US subsidiary of the company sells ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signs major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company’s performance during the reporting period.
won orders exceeding US $2.1 billion
According to the reporter, since the covid-19 self-test kit was approved in November last year, Andon Health Co.Ltd(002432) has received a total of US $2.108 billion in orders, which is about RMB 13.428 billion at the real-time US dollar exchange rate of 6.37, which is more than twice the total income of Andon Health Co.Ltd(002432) 2010 to 2020.
Covid-19 self-test kit has abundant production capacity and stable supply, which is Andon Health Co.Ltd(002432) the competitive advantage in the U.S. market. According to the capacity information disclosed by the company at the end of last year, the company’s covid-19 self-test kit had a monthly capacity of about 100 million people at that time. It is estimated that the capacity will increase to 200 million people per month by the beginning of 2022.
However, Andon Health Co.Ltd(002432) covid-19 self test kit has not yet entered the Chinese market. Since China liberalized antigen self-test in mid March, covid-19 antigen test products of more than 20 companies, including Guangzhou Wondfo Biotech Co.Ltd(300482) ( Guangzhou Wondfo Biotech Co.Ltd(300482) , SZ; closing price of 46.44 yuan yesterday), Beijing Hotgen Biotech Co.Ltd(688068) , Zhejiang Orient Gene Biotech Co.Ltd(688298) ( Zhejiang Orient Gene Biotech Co.Ltd(688298) , SH; closing price of 294.49 yuan yesterday), have been approved for listing, but Andon Health Co.Ltd(002432) is still absent.
According to informed sources, Andon Health Co.Ltd(002432) antigen detection kit is in the process of applying for listing in China. In addition, the reporter noted that covid-19 antigen self-test products of many Chinese enterprises have been authorized by FDA for emergency use recently. In addition to Andon Health Co.Ltd(002432) , there are Beijing Kur, Xiamen Bosheng biology, etc.
